ANLON HEALTHCARE IPO
Key IPO Details at a Glance
| IPO Period | 26th – 29th Aug 2025 |
|---|---|
| Listing on | 03 Sep 2025 |
| Price Band | ₹86 – ₹91 |
| Lot Size & Minimum Investment | 164 shares, amounting to ₹14,924 |
| Total Issue Size | ₹121.03 crores |
Important Dates for Investors
- Opening Date: 26 Aug 2025
- Closing Date: 29 Aug 2025
- UPI Payment Deadline: 29 Aug 2025 (5 PM)
- Allotment Announcement: 01 Sep 2025
- Refund Processing: 02 Sep 2025
- Demat Credit: 02 Sep 2025
- Stock Market Listing: 03 Sep 2025
- Mandate Validity End: 15 Sep 2025
- Anchor Investor Lock-in Release (50%): 01 Oct 2025
- Anchor Investor Lock-in Release (Remaining): 30 Nov 2025
*Dates may be revised as per official updates.
Understanding Anlon Healthcare’s Business
Anlon Healthcare, founded in 2013, operates in the pharmaceutical industry from Rajkot, Gujarat. Commencing manufacturing operations in 2017, the company specializes in Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and nutraceutical compounds. Its single manufacturing facility is ISO 9001:2015, GMP, and WHO-GMP certified, ensuring adherence to high quality standards. Anlon Healthcare serves pharmaceutical companies across India and exports to select international markets, demonstrating a growing global footprint.
IPO Structure and Capital Allocation
| Total Funds Raised | ₹121.03 crores |
|---|---|
| Fresh Issue Component | ₹121.03 crores |
| Offer for Sale Component | 0 |
The ANLON HEALTHCARE IPO is structured as a fresh issue, meaning all funds raised will directly flow into the company’s coffers. This entire issue size of ₹121.03 crores is dedicated to funding the company’s strategic growth initiatives, highlighting a clear intent to strengthen its financial and operational foundation.
Strategic Utilization of Proceeds
| Objective | Amount (INR Crores) | Allocation % |
|---|---|---|
| Capital expenditure for expansion | 30.71 | 25.37% |
| Repayment/pre-payment, in full or in part, of outstanding borrowings | 5.00 | 4% |
| Working capital requirements | 43.15 | 35.65% |
| General corporate purposes and miscellaneous | 42.17 | 35% |
Anlon Healthcare has outlined a clear strategy for deploying the capital raised from its IPO. A significant portion will fund capital expenditure for expansion (25.37%), vital for meeting demand. Another 4% is for repaying outstanding borrowings, reducing debt. The largest allocation, 35.65%, is designated for working capital, ensuring smooth operations. The remaining 35% covers general corporate purposes, offering flexibility for strategic needs. This plan underscores the company’s commitment to strengthening its infrastructure and optimizing financial health.
Core Advantages Driving Growth
- Diverse product portfolio with scalable business operations.
- Experienced promoters and a competent management team.
- High entry barriers due to strict approval standards.
- In-house testing ensures consistent quality and compliance.
- Emphasis on Quality, Environment, Health, and Safety (QEHS).
Anlon Healthcare benefits from a diverse product portfolio, scalable operations, and an experienced management team. High entry barriers in the pharma sector and strict regulatory standards are navigated effectively. In-house testing ensures consistent quality and compliance. An overarching emphasis on Quality, Environment, Health, and Safety (QEHS) reflects a responsible business model.
Key Considerations for Investors
- High dependency on a single manufacturing unit in Rajkot, Gujarat.
- Revenue concentration from the top few pharmaceutical industry customers.
- Limited experience in complex pharma intermediates manufacturing.
- Heavy reliance on select suppliers from western India.
- Delay in regulatory approvals can halt operations and revenue.
Key risks include high dependency on a single manufacturing unit in Rajkot, and revenue concentration from a few top customers. The company has limited experience in complex intermediates, potentially limiting diversification. Reliance on select Western Indian suppliers poses supply chain risks. Delays in regulatory approvals could also impact operations and revenue. Prospective investors should carefully evaluate these factors.
Insight into India’s Pharmaceutical Sector
India’s pharmaceutical industry stands as the world’s third-largest by volume, boasting a market size of ₹47,410 crores in Fiscal Year 2025. Projections indicate a robust growth trajectory, with an anticipated 10% Compound Annual Growth Rate (CAGR) to reach ₹73,270 crores by FY2030. This sector is significantly benefiting from the global “China+1” strategy, where international firms are diversifying their API sourcing to mitigate geopolitical risks and enhance supply chain resilience. However, the industry still faces a vulnerability, with over 70% of API raw materials being imported from China. To address this, the Indian government has launched strategic initiatives such as the Production Linked Incentive (PLI) scheme, with an outlay of ₹6,940 crores, and a ₹3,000 crore Bulk Drug Parks initiative. These programs are designed to boost domestic manufacturing capabilities and reduce reliance on imports, fostering self-sufficiency. India’s pharmaceutical exports reached ₹20,480 crores in FY25, showcasing a strong 14% year-on-year growth and reinforcing the nation’s position as a pivotal global pharmaceutical supplier. Anlon Healthcare operates within this dynamic and supportive ecosystem, aiming to capitalize on these macro-economic tailwinds.
Financial Performance Snapshot and Peer Comparison
Understanding Anlon Healthcare’s financial standing and how it compares to its peers is crucial for investors. As of its latest reported figures, Anlon Healthcare recorded a revenue of ₹120.29 crores, alongside a healthy EBITDA margin of 26.88%. Its Price-to-Earnings (P/E) ratio stands at 23.57x. When benchmarked against industry peers:
| Company | Revenue (₹Cr) | EBITDA Margin | P/E Ratio |
|---|---|---|---|
| Anlon Healthcare | 120.29 | 26.88% | 23.57x |
| Kronox Lab Sciences | 483.67 | 32.70% | 26.18x |
| AMI Organics | 670.37 | 12.79% | 61.6x |
| Supriya Organics | 527.13 | 31.60% | 31.1x |
While Anlon Healthcare’s revenue is comparatively smaller than its listed peers, its EBITDA margin of 26.88% is competitive, standing strong against Kronox Lab Sciences (32.70%) and Supriya Organics (31.60%), and notably higher than AMI Organics (12.79%). The P/E ratio of 23.57x places it at a reasonable valuation compared to Kronox Lab Sciences (26.18x) and significantly lower than AMI Organics (61.6x) and Supriya Organics (31.1x), suggesting potential for growth and a fair entry valuation for investors considering its current scale and profitability.
Investor Interest and Subscription Status
Subscription statistics based on the latest available information as of 5:00 PM on August 29, 2025, indicate varied interest across investor categories:
| Investor Category | Shares Reserved (Lakhs) | Shares Applied (Lakhs) | Subscription (Times) |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 99.75 | 106.89 | 1.07x |
| Non-Institutional Investors (NII) | 19.95 | 211.61 | 10.61x |
| Retail Individual Investors (RII) | 13.30 | 628.57 | 47.26x |
| Total | 133.00 | 947.08 | 7.12x |
*GMP figures are unofficial and may vary; exchange data is more reliable.
Participating in the ANLON HEALTHCARE IPO
Investors can participate in this IPO via the official Dhan Kirti IPO platform before the subscription closes.
The ANLON HEALTHCARE IPO offers a chance to invest in a growing pharmaceutical company with a focus on APIs and intermediates, operating in a robust industry supported by government initiatives. With a clear plan for capital utilization, strong operational foundations, and competitive financial metrics, Anlon Healthcare aims to capitalize on the increasing demand in the domestic and international pharmaceutical markets. As with any investment, it is advisable for prospective investors to conduct thorough due diligence and consult with a financial advisor to align with their investment objectives and risk appetite.
